Evidence map›Paper›PMID 39738752›Full record

ReviewMikrochimica acta2024

Cutting-edge 3D printing in immunosensor design for early cancer detection.

Sachin Kothawade, Vijaya Padwal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mikrochimica acta, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sachin KothawadeDepartment of Pharmaceutics, SCSSS's Sitabai, Thite College of Pharmacy, Shirur-412210, Dist-Pune, Maharashtra, India. sachin.kothawade23@gmail.com.ORCID http://orcid.org/0000-0002-8143-856X
Vijaya PadwalDepartment of Pharmaceutics, SCSSS's Sitabai, Thite College of Pharmacy, Shirur-412210, Dist-Pune, Maharashtra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a major cause of death globally, and early detection is a key to improving outcomes. Traditional diagnostic methods have limitations such as being invasive and lacking sensitivity. Immunosensors, which detect cancer biomarkers using antibodies, offer a solution with high sensitivity and selectivity. When combined with 3D printing, these immunosensors can be customized to detect specific cancer markers, creating rapid, cost-effective, and scalable diagnostic tools. The article reviews the principles behind immunosensors, different 3D fabrication methods such as Fused Deposition Modeling (FDM) and Stereolithography (SLA), and discusses how functionalization strategies, such as surface modifications, can enhance the sensitivity of these devices. The integration of 3D printing allows for the creation of complex sensor structures, offering advantages such as customization, rapid prototyping, and multi-material printing. These advancements make immunosensors arrays highly promising for early cancer detection, tumor profiling, and personalized medicine. The article also explores challenges like scalability, material biocompatibility, and the need for clinical validation. Future perspectives suggest the potential of integrating nanomaterials, multiplexed detection, and wearable technology to further improve the performance and accessibility of these diagnostic tools.

Indexed as

Biomarkers, TumorBiosensing TechniquesEarly Detection of CancerNeoplasmsPrinting, Three-DimensionalHumansImmunoassayBiomarkers, Tumor3D printingBiomarker detectionCancer diagnosticsImmunosensor arraysPersonalized medicineTumor profiling

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.